Brompheniramine Maleate, Pseudoephedrine Hydrochloride,
Prescription商品名: Brompheniramine maleate, pseudoephedrine hydrochloride,
About This Medication
DESCRIPTION Brompheniramine maleate, pseudoephedrine hydrochloride, and dextromethorphan hydrobromide syrup, 2 mg/30 mg/10 mg per 5 mL is a clear, light pink syrup with a butterscotch flavour. Each 5 mL (1 teaspoonful) contains: Brompheniramine Maleate, USP 2 mg Pseudoephedrine Hydrochloride, USP 30 mg Dextromethorphan Hydrobromide, USP 10 mg Alcohol 0.95% v/v In a palatable, aromatic vehicle. Inactive Ingredients: artificial butterscotch flavor, citric acid anhydrous, alcohol, FD&C Red No. 40, glycerin, sucrose, methylparaben, propylene glycol, purified water and sodium benzoate. It may contain 10% citric acid solution or 10% sodium citrate solution for pH adjustment. The pH range is between 4.0 and 6.0. Brompheniramine Maleate, USP(±)-2- p -Bromo-α-2-(dimethylamino)ethylbenzylpyridine maleate (1:1) Pseudoephedrine Hydrochloride, USP (+)-Pseudoephedrine hydrochloride Dextromethorphan Hydrobromide, USP 3-Methoxy-17-methyl-9α, 13α, 14α-morphinan hydrobromide monohydrate Antihistamine/Nasal Decongestant/Antitussive syrup for oral administration. bromfed-str1 bromfed-str2 bromfed-str3
有効成分
| 成分 | 含有量 |
|---|---|
| Brompheniramine Maleate | - |
| Dextromethorphan Hydrobromide | - |
| Pseudoephedrine Hydrochloride | - |
適応症と用法
用量と投与方法
Side Effects Overview
警告と注意事項
WARNINGS Especially in infants and small children, antihistamines in overdosage may cause hallucinations, convulsions, and death. Antihistamines may diminish mental alertness. In the young child, they may produce excitation.
禁忌
CONTRAINDICATIONS Hypersensitivity to any of the ingredients. Do not use in the newborn, in premature infants, in nursing mothers, or in patients with severe hypertension or severe coronary artery disease. Do not use dextromethorphan in patients receiving monoamine oxidase (MAOI) inhibitors (see PRECAUTIONS - Drug Interactions). Antihistamines should not be used to treat lower respiratory tract conditions including asthma.
Frequently Asked Questions
INDICATIONS AND USAGE For relief of coughs and upper respiratory symptoms, including nasal congestion, associated with allergy or the common cold.
DOSAGE AND ADMINISTRATION Adults and pediatric patients 12 years of age and over: 10 mL (2 teaspoonfuls) every 4 hours. Children 6 to under 12 years of age: 5 mL (1 teaspoonful) every 4 hours. Children 2 to under 6 years of age: 2.5 mL (½ teaspoonful) every 4 hours. Infants 6 months to under 2 years of age: Dosage to be established by a physician. Do not exceed 6 doses during a 24-hour period.
WARNINGS Especially in infants and small children, antihistamines in overdosage may cause hallucinations, convulsions, and death. Antihistamines may diminish mental alertness. In the young child, they may produce excitation.
CONTRAINDICATIONS Hypersensitivity to any of the ingredients. Do not use in the newborn, in premature infants, in nursing mothers, or in patients with severe hypertension or severe coronary artery disease. Do not use dextromethorphan in patients receiving monoamine oxidase (MAOI) inhibitors (see PRECAUTIONS - Drug Interactions). Antihistamines should not be used to treat lower respiratory tract conditions including asthma.
Brompheniramine Maleate, Pseudoephedrine Hydrochloride, is a prescription medication. You will need a valid prescription from a licensed healthcare provider.
Similar Liquid/Solution Products
Browse all Liquid/Solution products →References & Data Sources
- • DailyMed — Brompheniramine Maleate, Pseudoephedrine Hydrochloride, drug label (National Library of Medicine)
- • openFDA — Brompheniramine Maleate, Pseudoephedrine Hydrochloride, label data (U.S. Food & Drug Administration)
- • RxNorm — RXCUI 1357010 (NLM Normalized Drug Names)
- • NDC Directory — Brompheniramine Maleate, Pseudoephedrine Hydrochloride, (FDA National Drug Code)
医療免責事項
このページの情報は教育目的のみを意図しており、専門家による医療アドバイス、診断、または治療の代替として使用すべきではありません。
疾患や医薬品に関するご質問がある場合は、必ず担当医またはその他の資格を持つ医療専門家にご相談ください。
データソース: DailyMed (NLM), openFDA, MFDS